The prognostic impact of germline 46/1 haplotype of Janus Kinase 2 in cytogenetically normal acute myeloid leukemia

Haematologica

Volumn 96, Issue 11, 2011, Pages 1613-1618

  Nahajevszky, Sarolta ^a   Andrikovics, Hajnalka ^b   Batai, Arpad ^a   Adam, Emma ^a   Bors, Andras ^b   Csomor, Judit ^a   Gopcsa, Laszlo ^a   Koszarska, Magdalena ^b   Kozma, Andras ^a   Lovas, Nora ^a   Lueff, Sandor ^a   Matrai, Zoltan ^a   Meggyesi, Nora ^b   Sinko, Janos ^a   Sipos, Andrea ^a   Varkonyi, Andrea ^a   Fekete, Sandor ^a   Tordai, Attila ^b   Masszil, Tamas ^a,c  

^a Szent Laszlo Hospital   (Hungary)

^b Hungarian National Blood Transfusion Service   (Hungary)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

46 1 haplotype; Acute myeloid leukemia; Janus Kinase 2; Prognosis

Indexed keywords

JANUS KINASE 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; APLASIA; ARTICLE; CYTOGENETICS; DEATH; DISEASE FREE SURVIVAL; FEMALE; GENETIC LINKAGE; GENOTYPE; HAPLOTYPE; HIGH RESOLUTION MELTING ANALYSIS; HOMOZYGOSITY; HUMAN; INFECTION; KARYOTYPE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GERM-LINE MUTATION; HAPLOTYPES; HUMANS; JANUS KINASE 2; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SURVIVAL RATE;

EID: 80355126548     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.043885     Document Type: Article

References (42)

1. Stone RM. Prognostic factors in AML in relation to (ab)normal karyotype. Best Pract Res Clin Haematol. 2009;22(4):523-528.
2. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352 (17):1779-1790.
3. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397.
4. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.
5. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446-449.
6. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009;41(4):455-459.
7. Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450-454.
8. Pardanani A, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Hanson CA, et al. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia. 2010;24(1):110-114.
9. Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ, et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia. 2010;24(1):105-109.
10. Frohling S, Lipka DB, Kayser S, Scholl C, Schlenk RF, Dohner H, et al. Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood. 2006; 107(3):1242-1243.
11. Ingram W, Lea NC, Cervera J, Germing U, Fenaux P, Cassinat B, et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia. 2006;20(7):1319-1321.
12. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106(10):3370-3373.
13. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005; 106(6):2162-2168.
14. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005;106(10): 3377-3379.
15. Andrikovics H, Nahajevszky S, Koszarska M, Meggyesi N, Bors A, Halm G, et al. JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia. Leukemia. 2010;24(10):1809-18013.
16. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
17. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the UnitedKingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752-1759.
18. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107(10):4011-4020.
19. Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22(15):1928-1929.
20. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-19018.
21. Kuptsova N, Kopecky KJ, Godwin J, Anderson J, Hoque A, Willman CL, et al. Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. Blood. 2007;109(9):3936-3944.
22. Monzo M, Brunet S, Urbano-Ispizua A, Navarro A, Perea G, Esteve J, et al. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood. 2006;107(12):4871-4879.
23. Seedhouse CH, Grundy M, White P, Li Y, Fisher J, Yakunina D, et al. Sequential influences of leukemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials. Clin Cancer Res. 2007;13(23):7059-7066.
24. Damm F, Heuser M, Morgan M, Yun H, Grosshennig A, Gohring G, et al. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2010;28(4):578-585.
25. Wagner K, Damm F, Gohring G, Gorlich K, Heuser M, Schafer I, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol. 2010;28(14):2356-2364.
26. Chen BA, Zhong YJ, Feng JF, Li YF, Ding JH, Gao C, et al. Association of Janus kinase 2(JAK2) A830G polymorphism with acute leukemia susceptibility. Blood. 2009;114 (22):629.
27. Zhong Y, Chen B, Feng J, Cheng L, Li Y, Qian J, et al. The associations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomes in patients with acute myeloid leukemia. Leuk Lymphoma. 2010;51(6):1115-1120.
28. The International HapMap Consortium. The International HapMap Project. Nature. 2003;426(6968): 789-96.
29. Campbell PJ. Somatic and germline genetics at the JAK2 locus. Nat Genet. 2009; 41(4):385-386.
30. Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL, et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia. 2006; 20(6):971-978.
31. Ferguson LR, Han DY, Fraser AG, Huebner C, Lam WJ, Morgan AR, et al. Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STATJAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat Res. 2010;690(1-2):108-115.
32. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, et al. Metaanalysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43(3):246-252.
33. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 2009;58(8):1152-1167.
34. Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut. 2011 Feb 7. [Epub ahead of print]
35. Brosbol-Ravnborg A, Hvas CL, Agnholt J, Dahlerup JF, Vind I, Till A, et al. Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and - independent pathways. Clin Exp Immunol. 2009;155(3):487-495.
36. Han X, Uchida K, Jurickova I, Koch D, Willson T, Samson C, et al. Ranulocytemacrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease. Gastroenterology. 2009;136(4):1261-71, e1-3.
37. Goldstein JI, Kominsky DJ, Jacobson N, Bowers B, Regalia K, Austin GL, et al. Defective leukocyte GM-CSF receptor (CD116) expression and function in inflammatory bowel disease. Gastroenterology. 2011;141(1):208-216.
38. Thalhammer F, Geissler K, Jager U, Kyrle PA, Pabinger I, Mitterbauer M, et al. Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann Hematol. 1996;72(4): 216-222.
39. Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol. 1998;58(2):105-109.
40. Steinmetz HT, Schulz A, Staib P, Scheid C, Glasmacher A, Neufang A, et al. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol. 1999;78(9): 418-425.
41. Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, et al. AIDA (alltrans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood. 1996;88(4):1390-1398.
42. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331 (14):896-903.